Find A Research Study
Study Title: Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer (RTOG 0524)
Category: Cancer, General
Currently accepting participants?
Yes - please read the description below and contact the study coordinator if you are interested.
Principal Investigator: Huong Pham
Study Coordinator: Kathy Rabena
Phone: (206) 223-6892 Ext.36892
Email: hemkcr@vmmc.org
What is the Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer (RTOG 0524) study?
Who can participate?
~Histologically or cytological confiramtion of Transitional Cell Carcinoma (TCC) of the bladder with mauscularis propria invasion.
~Must be registered within 12 weeks of diagnosis
~Judged to be medically inapporiate for radical cystectomy
~Must have sufficient tumore tissue available for her2/neu analysis
Ineligibility:
~Prior invasive mailignancy unless disease free for a minimum of 3 years
~Previous systemice chemotherapy of any sort for TCC
~Previous radiation therapy (includes seed implantation)
What do I have to do as a study participant?
Study Summary:
Detailed Study Description:
Study Design: Interventional
Phase of Study: Phase I / II
Study Type: Interventional
Condition or Study Focus: Bladder Cancer
Intervention Type: biological
Intervention Name: Trastuzumab
Gender: Male and Female
Age group: Interventional
Sponsor: Radiation Therapy Oncology Group
Other studies in this category include:
Studies currently accepting study participants:
- A Randomized Phase III Study of Sublobar Resection versus Sublobar Resection plus Brachytherapy in High Risk Patients with Non-Small Cell Lung Cancer (NSCLC),
- A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by Surgery for Selected Patients for Stage III and IV Head and Neck Carcinomas
- AMC045: HIV-Associated Anal Cancer
- AMC047: AIDS-Associated B-Cell Non-Hodgkin's Lymphoma
- Brain Metastases in NSCLC (RTOG 0320)
- Investigational drug vs. Placebo for Patients with Renal Cell Carcinoma (Kidney Cancer) at High Risk of Recurrence after Surgery
- Lymphoma (S0313)
- Maintenance therapy for advanced ovarian or peritoneal cancer (GOG 0212)
- Newly diagnosed, untreated ovarian or peritoneal cancer (GOG 0218)
- Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer (RTOG 0524)
- PGT307 - Paclitaxel Poliglumex plus Carboplatin for the treatment of non-small cell lung cancer in women.
- Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
- Sorafenib v. Sunitinib v. Placebo for High Risk Renal Cell Carcinoma Patients
- Sorafenib vs Placebo for Hepatocellular Carcinoma
- Stage IV Urothelial Cancer
- SWOG S0016
- Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced RCC Who Failed First-Line Sunitinib
- Trial of FOLFOX with or without cetuximab for colon cancer
- Use of Human Corticotropin-Releasing Factor (hCRF) to Control Brain Swelling (edema) in Brain Tumor Patients
- Weekly Topotecan (HyCamtin®) with Bevacizumab (Avastin®) Ovarian, Fallopian tube and/or Peritoneal Cancer
Studies currently not accepting study participants:
- Methylphenidate in Treating Patients With Fatigue Caused by Cancer
- MK0646 for Patients with Advanced Cancer
- Open Label Study of Human Corticotropin-Releasing Factor (hCRF)
- Phase I, oral agent for Advanced Cancers
- Randomized Study comparing Human Corticotropin-Releasing Factor to Placebo for Patients Requiring High-dose Dexamethasone
- Weekly IV of Hymcamtin in Combination with Carboplatin as Second Line Therapy in Potentially Platinum-Sensitive Reaplased Ovarian Cancer